fundvisualizer.com

Hartford International Opp HLS IBHBIOX

Performance (before sales charge)

As of 09/30/2024

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. After-sales-charge returns reflect the maximum sales charge applicable to the fund. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

Asset allocation

As of 08/31/2024
Stock
2.51%
Non-U.S. Stock
96.56%
Bond
0.00%
Non-U.S. Bond
0.00%
Preferred
0.00%
Convertible
0.00%
Cash
0.93%
Other
0.00%

Due to rounding, percentages may not equal 100%.

Sectors

As of 08/31/2024

Basic materials

4.99%

Consumer cyclical

8.14%

Financial services

20.27%

Real estate

0.50%

Consumer defensive

4.93%

Health care

10.15%

Utilities

2.97%

Communication services

7.09%

Energy

5.81%

Industrials

14.72%

Technology

18.82%

Top 10 holdings

As of 08/31/2024

Taiwan Semiconductor Manufacturing Co Ltd
3.57%
Tencent Holdings Ltd
2.49%
AstraZeneca PLC
2.34%
Unilever PLC
2.31%
Samsung Electronics Co Ltd
2.28%
Shell PLC
2.23%
Novo Nordisk AS Class B
2.20%
ASML Holding NV
2.10%
Novartis AG Registered Shares
2.09%
Allianz SE
2.03%
Fund assets

$898.6 Million

Share class

Inst

Morningstar category

Foreign Large Blend

Expense ratio

1.01%

Investment objective

Foreign Stock

Documents